Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

British Medical Journal

Volumn 324, Issue 7329, 2002, Pages 71-86

  Baigent, C ^a   Sudlow, C ^a   Collins, R ^a   Peto, R ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE;

ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STROKE; VASCULAR DISEASE; ACUTE HEART INFARCTION; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG MEGADOSE; FATALITY; LUNG EMBOLISM; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; ACUTE DISEASE; ANTICOAGULANT THERAPY; CORONARY ARTERY OCCLUSION; PREVENTION STUDY; THERAPY EFFECT; TREATMENT OUTCOME;

ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 0037065502     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
2. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy
3. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
4. Antithrombotic therapy in acute ischaemic stroke: An overview of the completed randomised trials
5. Clinical pharmacology of platelet cyclo-oxygenase inhibition
6. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
8. Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction
9. Tidopidine in the prevention of the block of aorto-coronary by-pass
10. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
11. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
12. Reliable assessment of the effects of treatment on mortality and major morbidity. I. Clinical trials
13. Aspirin use and reduced risk of fatal colon cancer
14. Aspirin use and chronic diseases: A cohort study of the elderly
15. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
16. European stroke prevention study. 2. Efficacy and safety data
17. The international Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
18. CAST: Randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke
19. Indications for early aspirin use in acute ischemic stroke. A combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial
20. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
21. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
22. Evolving trends in the epidemiology of heart failure: A rationale for prevention
23. Atrial fibrillation as an independent risk factor for stroke: The Framingham study
24. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
25. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study
26. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14
27. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus
28. Aspirin and restenosis after successful PTCA: Comparison of 1400 mg v 350 mg daily in a double-blind study
29. Acetylsalicyclic acid-reocclusion-prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease
30. A comparison of two doses of aspirin (30 mg v 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
31. Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease
32. Low-dose aspirin and stroke. "It ain't necessarily so"
33. Aspirin dose in stroke prevention. Beautiful hypotheses slain by ugly facts
34. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
35. Comparative safety and tolerability of clopidogrel versus aspirin. Results from CAPRIE
36. The antiaggregating and antithrombotic activity of ticlopidine
37. Antiplatelet rather than anticoagulant therapy with coronary stenting
38. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
39. Effects of clopidogrel in addition to aspirin in patients with non-ST segment elevation acute coronary syndromes
40. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
41. Safe use of platelet GP IIb/IIIa inhibitors
42. Aspirin therapy in diabetes
43. Antithrombotic therapy in heart failure: New perspectives
44. Premature cardiovascular disease in chronic renal failure
45. Aspirin and human platelets: From clinical trials to acetylation of cyclooxygenase and back
46. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
47. Thienopyridines versus aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease. A systematic review of the evidence from randomized trials
48. Clinical outcome of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
49. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
50. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention
51. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists
52. Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin
53. Rationale, design and organisation of the second Chinese cardiac study (CCS-2): A raudomised trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction
54. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiological studies
55. Aspirin use is low among United States outpatients with coronary artery disease
56. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice
57. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease: Early safety and efficacy experience
58. Recent national patterns of warfarin use in atrial fibrillation
59. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community
60. A survey of atrial fibrillation in general practice: The west Birmingham atrial fibrillation project
61. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs Medical Center